KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xenon Pharmaceuticals (XENE) Shares Issued (2016 - 2025)

Xenon Pharmaceuticals (XENE) has disclosed Shares Issued for 13 consecutive years, with $1.4 million as the latest value for Q4 2025.

  • On a quarterly basis, Shares Issued rose 2848.94% to $1.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was $5.0 million, a 10457.45% increase, with the full-year FY2025 number at $5.0 million, up 10457.45% from a year prior.
  • Shares Issued was $1.4 million for Q4 2025 at Xenon Pharmaceuticals, down from $2.4 million in the prior quarter.
  • In the past five years, Shares Issued ranged from a high of $7.9 million in Q1 2022 to a low of -$29.5 million in Q4 2023.
  • A 5-year average of -$1.4 million and a median of $85500.0 in 2021 define the central range for Shares Issued.
  • Peak YoY movement for Shares Issued: skyrocketed 7330.19% in 2022, then crashed 491316.67% in 2023.
  • Xenon Pharmaceuticals' Shares Issued stood at $15000.0 in 2021, then tumbled by 60.0% to $6000.0 in 2022, then plummeted by 491316.67% to -$29.5 million in 2023, then skyrocketed by 100.16% to $47000.0 in 2024, then skyrocketed by 2848.94% to $1.4 million in 2025.
  • Per Business Quant, the three most recent readings for XENE's Shares Issued are $1.4 million (Q4 2025), $2.4 million (Q3 2025), and $65000.0 (Q2 2025).